Humatin (Paromomycin Sulfate)

Humatin is indicated for the treatment of several protozoal infections where paromomycin has demonstrated efficacy. It is prescribed for both intestinal and skin manifestations of specific parasitic diseases.

• Amebiasis caused by Entamoeba histolytica, particularly intestinal infection.
• Giardiasis due to Giardia lamblia, including chronic diarrheal cases.
• Cutaneous leishmaniasis caused by Leishmania species, for localized skin lesions.
• Cryptosporidiosis associated with Cryptosporidium parvum or C. hominis infection.
• Off‑label or investigational use in other protozoal infections as guided by clinical judgment.
• Prevention of relapse in patients with persistent infection after initial therapy.

• Paromomycin sulfate exerts its antimicrobial activity by binding to the 30S ribosomal subunit of susceptible microorganisms. This interaction interferes with the initiation complex of protein synthesis, causing misreading of mRNA and premature termination of peptide chains. In protozoa, the same ribosomal binding leads to inhibition of essential protein production, resulting in cell death. The drug’s poor systemic absorption after oral administration concentrates activity within the gastrointestinal lumen and superficial skin lesions.

Adverse reactions to Humatin are generally mild but can include more serious events that require medical attention.

Common

• Nausea or vomiting
• Diarrhea or abdominal cramping
• Metallic taste in the mouth
• Skin rash or pruritus
• Headache or dizziness
• Loss of appetite
• Mild abdominal discomfort
• Transient fever
• Dry mouth
• Taste alteration
• Mild insomnia

Serious

• Ototoxicity presenting as hearing loss or tinnitus
• Nephrotoxicity with elevated serum creatinine
• Severe allergic reactions such as angioedema or anaphylaxis
• Clostridioides difficile–associated colitis
• Cardiac arrhythmias in patients with pre‑existing heart disease
• Liver enzyme elevations indicating hepatic stress
• Seizures in patients with renal impairment
• Severe electrolyte disturbances such as hypokalemia
• Bone marrow suppression leading to neutropenia

When prescribing Humatin, clinicians should evaluate patient history and monitor for conditions that could increase the risk of toxicity or reduce therapeutic benefit.

• Assess renal function before initiation and adjust therapy if creatinine clearance is reduced.
• Use caution in patients with pre‑existing hearing loss, as ototoxicity may be potentiated.
• Monitor liver enzymes during prolonged treatment courses.
• Avoid use during pregnancy or lactation unless the potential benefit outweighs the risk.
• Review concomitant medications for nephrotoxic or ototoxic potential.
• Educate patients to report any sudden hearing changes, rash, or severe gastrointestinal symptoms promptly.

Paromomycin may interact with other agents that affect renal function, hearing, or intestinal flora, and certain drugs can alter its absorption.

Avoid

• Concurrent use of other aminoglycosides (e.g., gentamicin, amikacin) due to additive ototoxic and nephrotoxic risk.
• Co‑administration with loop diuretics such as furosemide, which can potentiate renal toxicity.
• Combining with high‑dose oral vancomycin, which may increase gastrointestinal adverse effects.

Use with caution

• Concurrent nephrotoxic agents like NSAIDs or cisplatin; monitor renal parameters closely.
• Other ototoxic medications such as vancomycin or erythromycin; observe for hearing changes.
• Probiotic or antibiotic therapy that may alter gut microbiota and affect efficacy.